Detection and treatment of drug-resistant tuberculosis (TB) was not a priority in South Africa prior to 2005. Surveillance of resistance to isoniazid, rifampicin, ethambutol, and streptomycin undertaken in 2001-2002 found that 1.8% of new TB patients and 6.7% of previously treated TB patients had multidrug resistant (MDR)-TB. Eight-percent of strains were resistant to at least one drug and 20 (0.5%) were resistant to all four tested drugs. The standardized treatment adopted for MDR-TB at that time was an intensive phase of kanamycin, ethionamide, pyrazinamide, ofloxacin, and cycloserine or ethambutol followed by 12-18 months of ethionamide, ofloxacin, and cycloserine or ethambutol. Testing for resistance to second-line drugs was not routinely undertaken. In 2005 an investigation into the unusually high death rate among TB patients in Tugela Ferry in KwaZulu-Natal revealed a nosocomial outbreak of extensively drug-resistant (XDR)-TB. A death rate of over 95% was recorded in the 1st year, including health workers at the hospital. South African guidelines were reviewed and susceptibility testing for ofloxacin and amikacin was introduced in 2007 for all MDR-TB cases with capreomycin and p-aminosalicylic acid made available for the treatment of XDR-TB. Unfortunately, MDR cure rates remained poor and between 2007 and 2010 the number of confirmed XDR-TB cases in South Africa rose from 458 to 741. In 2010 the MDR treatment regimen was amended to replace ethambutol with pyrazinamide and provide the option of replacing cycloserine with terizidone. Standardized XDR treatment involved capreomycin, ethionamide,
p-aminosalicylic acid, moxifloxacin, and terizidone or cycloserine. The number of XDR cases has continued to rise as have the number of ''treatment failures," which in 2015 were estimated to comprise around 500 individuals.
Extended drug susceptibility testing is not routinely provided in South Africa but data provided by research studies suggests high levels of resistance to second-line drugs among patients with XDR-TB. In a prospective study in the Western Cape of 179 newly diagnosed XDR patient isolates, 43% were found to be resistant to at least 10 drugs. For such patients construction of an effective regimen may not be possible and on failing treatment they may be discharged home. In the Western Cape study 35/104 (35%) of the home discharged ''programmatically incurable" TB patients were smear positive. Whole genome sequencing identified 17 clusters of strains or two or more patients with a difference of less than two single nucleotide polymorphisms and identical genotypic resistance patterns, suggesting a high likelihood of transmission.
Access to the new drugs bedaquiline and delamanid has been very limited in South Africa but is improving. Resistance to these drugs is currently low. However, access to new drugs is restricted by the need to include at least four effective drugs in the regimen. In addition, individuals with ongoing substance abuse problems (a risk factor for drug resistance) are considered to be unsuitable for treatment with new drugs. Thus, a significant pool of patients with incurable TB is likely to remain and strategies are urgently needed to prevent further nosocomial and community-based transmission. 
